1. Search Result
Search Result
Results for "

C57BL6/J mouse

" in MedChemExpress (MCE) Product Catalog:

3400

Inhibitors & Agonists

1

Screening Libraries

15

Fluorescent Dye

34

Biochemical Assay Reagents

281

Peptides

25

MCE Kits

417

Inhibitory Antibodies

313

Natural
Products

2098

Recombinant Proteins

74

Isotope-Labeled Compounds

51

Antibodies

7

Click Chemistry

760

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-N0538

    Xylite

    Autophagy Endogenous Metabolite Bacterial Atg7 Atg8/LC3 Metabolic Disease Cancer
    Xylitol can be classified as a polyol and sugar alcohol, exhibiting inhibitory activity on cancer cell proliferation. It induces autophagy (Autophagy) and cell death in A549 cells by activating the autophagy signaling pathway, as evidenced by the increased expression of LC3-II and Atg5-Atg12 upon Xylitol treatment. Additionally, Xylitol inhibits acetaldehyde production by Candida species, thereby reducing their carcinogenic potential. In vivo, Xylitol induces alterations in the gut microbiota of mice, which may enhance cholesterol accumulation and upregulate hepatic ChREBP, while also slowing tumor growth in the B16F10 melanoma C57BL/6 mouse model .
    Xylitol
  • HY-117427

    Stearoyl-CoA Desaturase (SCD) Metabolic Disease
    D5D-IN-326 is a selective, orally active delta-5 desaturase (D5D) inhibitor, with IC50s of 72 and 22 nM for rat and human D5D in enzymic and cell-based assays, respectively, has no effect on D6D or D9D activity. D5D-IN-326 reduces insulin resistance and decreases body weight in diet-induced obese C57BL/6J mice .
    D5D-IN-326
  • HY-169953

    Pyk2 Metabolic Disease
    BT-Amide is the orally active inhibitor for Pyk2 kinase with IC50 of 44.69 nM. BT-Amide prevents glucocorticoid-induced bone loss, exhibits bone protective activity in C57BL/6 mouse .
    BT-Amide
  • HY-160025

    Indoleamine 2,3-Dioxygenase (IDO) Cancer
    IDO antagonist-1 (compound 163) is an antagonist of IDO . IDO antagonist-1 inhibits pancreatic adenocarcinoma cells growth in C57BL/6 mice .
    IDO antagonist-1
  • HY-157429

    5-HT Receptor Neurological Disease
    25N-N1-Nap (compound 16) is a β-arrestin-biased 5-HT2A agonist. 25N-N1-Nap antagonizes phencyclidine induced hyperactivity in Male C57BL/6 J mice .
    25N-N1-Nap
  • HY-170362

    Cyclic GMP-AMP Synthase Inflammation/Immunology
    cGAS-IN-4 (Compound 36) is an orally active inhibitor for cyclic GMP-AMP synthase (cGAS) with IC50 of 32 nM and 5.8 nM for h-cGAS and m-cGAS. cGAS-IN-4 inhibits the cGAMP in THP-1 cell with an IC50 of 60 nM, which improves the cellular potency. cGAS-IN-4 exhibits anti-inflammatory efficacy in Concanavalin A (HY-P2149)-induced acute liver injury in mouse models . orally active, THP-1, C57Bl/6 mouse, orally active
    cGAS-IN-4
  • HY-168081

    PD-1/PD-L1 Cancer
    PD-1/PD-L1-IN-52 (Compound III-5) is an orally active PD-1/PD-L1 inhibitor that blocks the interaction between PD-1 and PD-L1, with an IC50 of 109.9 nM. PD-1/PD-L1-IN-52 exhibits antitumor activity in a C57BL/6 mouse xenograft model implanted with human PD-1-expressing MC38 colon cancer cells, with a TGI of 49.6% .
    PD-1/PD-L1-IN-52
  • HY-128435

    Estrogen Receptor/ERR Metabolic Disease
    2,4'-Dihydroxybenzophenone ((Z)-SU4312) exhibited estrogenic activities. 2,4'-Dihydroxybenzophenone has oral bioactivity that can effectively protect C57BL/6J mice from Acetaminophen (HY-66005, APAP)-induced hepatotoxicity .
    2,4'-Dihydroxybenzophenone-1
  • HY-144743

    Phosphodiesterase (PDE) Others
    ATX inhibitor 12 (compound 20) is an orally active and potent ATX (autotaxin) inhibitor, with an IC50 of 1.72 nM. ATX inhibitor 12 effectively alleviates lung structural damage with fewer fibrotic lesions at an oral dose of 60 mg/kg in C57Bl/6J mice. ATX inhibitor 12 can be uesd for idiopathic pulmonary fibrosis (IPF) research .
    ATX inhibitor 12
  • HY-N12375

    Others Others
    Kadsuphilin J is a lignan isolated from the roots of K. longipedunculata
    Kadsuphilin J
  • HY-P5169

    Amino Acid Derivatives Inflammation/Immunology
    LVGRQLEEFL (mouse) can be named as G * peptide, corresponding to amino acids 113 to 122 in apolipoprotein J ([113,122] apoJ)}. LVGRQLEEFL (mouse) exhibits anti-inflammatory and anti-atherogenic properties. LVGRQLEEFL (mouse) can be added to an apoJ mimetic, to form HM-10/10 peptide, which is a mimetic peptide and a novel chimeric high density lipoprotein. HM-10/10 peptide protects retinal pigment epithelium (RPE) and photoreceptors from oxidant induced cell death .
    LVGRQLEEFL (mouse)
  • HY-P5169A

    Amino Acid Derivatives Inflammation/Immunology
    LVGRQLEEFL (mouse) TFA can be named as G * peptide, corresponding to amino acids 113 to 122 in apolipoprotein J ([113,122] apoJ)}. LVGRQLEEFL (mouse) TFA exhibits anti-inflammatory and anti-atherogenic properties. LVGRQLEEFL (mouse) TFA can be added to an apoJ mimetic, to form HM-10/10 peptide, which is a mimetic peptide and a novel chimeric high density lipoprotein. HM-10/10 peptide protects retinal pigment epithelium (RPE) and photoreceptors from oxidant induced cell death .
    LVGRQLEEFL (mouse) (TFA)
  • HY-103360
    J-113863
    3 Publications Verification

    CCR Inflammation/Immunology
    J-113863 is a potent and selective CCR1 antagonist with IC50 values of 0.9 nM and 5.8 nM for human and mouse CCR1 receptors, respectively. J-113863 is also a potent antagonist of the human CCR3 (IC50 of 0.58 nM) , but a weak antagonist of the mouse CCR3 (IC50 of 460 nM). J-113863 is inactive against CCR2, CCR4 and CCR5, as well as the LTB4 or TNF-α receptors. Anti-inflammatory effect .
    J-113863
  • HY-110216

    CRAC Channel Inflammation/Immunology
    5J-4 is a potent CRAC inhibitor. 5J-4 decreases the numbers of infiltrated mononuclear cell into the CNS, and significantly decreases the population of infiltrated CD4+ population. 5J-4 reduces the symptoms and delayed the onset of EAE (experimental autoimmune encephalomyelitis) in mouse model of inflammation .
    5J-4
  • HY-155172

    Cyclophilin Cancer
    ZX-J-19j (Compound ZX-J-19j) is a cyclophilin J inhibitor. ZX-J-19j showes potent antitumor activity .
    ZX-J-19j
  • HY-19301

    J-104135

    Farnesyl Transferase Cancer
    J 104871 (J-104135) is a farnesyl pyrophosphate (FPP)-competitive farnesyltransferase (FTase) inhibitor. J 104871 inhibits rat brain FTase with an IC50 of 3.9 nM in the presence of farnesyl pyrophosphate (FPP) .
    J 104871
  • HY-P2424

    CCK-J

    Calcium Channel Others
    Cholecystokinin-J (CCK-J), a cholecystokinin, stimulates Ca 2+ release .
    Cholecystokinin-J
  • HY-145855

    TGF-β Receptor Inflammation/Immunology
    J-1063 is a potent, selective and orally active ALK5 inhibitor with an IC50 of 0.039 µM. J-1063 shows anti-fibrotic effect by the inhibition of inflammatory infiltration, collagen deposition, and hepatocytes necrosis. J-1063 has the potential for the research of liver fibrosis .
    J-1063
  • HY-129826

    mAChR Others
    J-104129 is a selective and orally active muscarinic M3 receptor antagonist (Ki = 4.2 nM). J-104129 is effective in promoting bronchodilation .
    J-104129
  • HY-163429

    TGF-β Receptor p38 MAPK Inflammation/Immunology Cancer
    J-1149 is a potent ALK5 inhibitor, with an IC50 value of 0.017 μM. J-1149 also shows weak p38α MAP kinase inhibitory activity, with an IC50 value of 0.435 μM. J-1149 can be used for liver fibrosis research .
    J-1149
  • HY-107653

    mAChR Neurological Disease
    J 104129 fumarate is a selective and orally active muscarinic M3 antagonist with Ki values of 4.2 nM and 490 nM for M3 and M2, respectively. J 104129 fumarate antagonized ACh-induced bronchoconstriction. J 104129 fumarate has the potential for the research of obstructive airway disease .
    J 104129 fumarate
  • HY-107721

    Opioid Receptor Neurological Disease
    (±)-J-113397 is a potent and selective non-peptidyl ORL1 receptor antagonist with a Ki of 1.8 nM for cloned human ORL1. J-113397 inhibited nociceptin/orphanin FQ-stimulated GTPγS binding to CHO cells expressing ORL1 with an IC50 value of 5.3 nM. J-113397 can be used for researching the physiological roles of nociceptin/orphanin FQ .
    (±)-J-113397
  • HY-149403

    Anaplastic lymphoma kinase (ALK) Others
    J-1048 is an activin receptor-like kinase 5 (ALK5) inhibitor. J-1048 can inhibit TAA-induced liver fibrosis in mice by explicitly blocking the TGF-β/Smad signaling pathway .
    J-1048
  • HY-118809

    NSC 321569; J 2532

    Drug Derivative Others
    J 2931 is an active compound.
    J 2931
  • HY-114072A

    Opioid Receptor Neurological Disease
    (S,S)-J-113397 is an isomer of J-113397 (HY-114072). J-113397 is an Opioid Receptor antagonist .
    (S,S)-J-113397
  • HY-103360A

    UCB35625

    CCR Inflammation/Immunology
    cis-J-113863 is a competitive chemokine receptor 1 (CCR1) antagonist, with IC50 values of 0.9 and 5.8 nM for human and mouse CCR1 receptors, respectively .
    cis-J-113863
  • HY-126873

    Drug Derivative Others
    Nikkomycin J is an active compound. Nikkomycin J can be used for various researches .
    Nikkomycin J
  • HY-13779A

    Monoamine Oxidase Dopamine Transporter Neurological Disease
    J147 is an exceptionally potent, orally active, neuroprotective agent for cognitive enhancement. J147 can pass the blood brain barrier (BBB). J147 can inhibit monoamine oxidase B (MAO B) and the dopamine transporter. J147 plays an impotant role in Alzheimer’s disease (AD) .
    J147
  • HY-149714

    ICMT Cancer
    J6-3 is an inhibitor of ICMT with an IC50 of 0.6 μM and has anticancer activity. J6-3 inhibits MDA-MB231 cells with an IC50 of 3.4 μM .
    J6-3
  • HY-111615

    Somatostatin Receptor Neurological Disease
    J-2156 is a high potent, selective somatostatin receptor type 4 (SST4 receptor) agonist with IC50s of 0.05 nM and 0.07 nM for human and rat SST4 receptors, respectively. J-2156 is used for the relief of mechanical allodynia and mechanical hyperalgesia in the ipsilateral hindpaws in rats .
    J-2156
  • HY-155699

    HDAC Inflammation/Immunology
    J27644 is a potent HDAC inhibitor. J27644 mitigates TGF-β-induced pulmonary fibrosis .
    J27644
  • HY-N14365

    Bacterial Infection
    Sannamycin J is an aminoglycoside antibiotic. Sannamycin J can be found in Streptomyces sannanensis sp. KC-7038. Sannamycin J has weak antibacterial activity against Gram-positive bacteria and Gram-negative bacteria .
    Sannamycin J
  • HY-122021

    Neuropeptide Y Receptor Neurological Disease
    J-115814 is a potent and selective neuropeptide Y1 antagonist with Ki values of 1.4, 1.8, 1.9, >10000, 620, 6000, >10000 nM for hY1, rY1, mY1, hY2, hY4, hY5, mY6, respectively. J-115814 inhibits feeding behaviors .
    J-115814
  • HY-113366S

    Isotope-Labeled Compounds Others
    Prostaglandin J2-d4 is the deuterium labeled Prostaglandin J2[1].
    Prostaglandin J2-d4
  • HY-N13315

    Others Neurological Disease
    Otophylloside J is a pregnane glycosides isolated from the roots of Cynanchum otophyllum. Otophylloside J can be used in epilepsy research .
    Otophylloside J
  • HY-15648H

    Histone Demethylase Parasite Cancer
    GSK-J5 hydrochloride is a cell-permeable ester derivative of GSK J2 (HY-15648A), inactive. GSK-J5 hydrochloride is also an isomer of GSK-J4 (HY-15648B) and often used as a negative group .
    GSK-J5 hydrochloride
  • HY-N12137

    Others Cancer
    Glycoside St-J (Compound 2) is a triterpenoid saponin. Glycoside St-J has antitumor activity and inhibits HeLa cell proliferation. Glycoside St-J Isolates from natural Anemone flaccida. Glycoside St-J can be used in the development of new anticancer agents .
    Glycoside St-J
  • HY-119550

    HDAC Parasite Infection
    J1075 is a selective Schistosoma mansoni HDAC8 inhibitor (with decreased affinity for human HDAC8). J1075 can induce apoptosis (Apoptosis) and death in schistosome cells. J1075 holds research value in the field of anti-parasitic agents .
    J1075
  • HY-N9005

    Others Cardiovascular Disease
    Dysolenticin J has potent vasodilative effects on aortic rings. Dysolenticin J is an alkaloid that can be isolated from Dysoxylum lenticellatum .
    Dysolenticin J
  • HY-157269

    Others Inflammation/Immunology
    J10-1 is a hapten. J10-1 promotes peptide exchange of all DR alleles (DR1, DR2, DR4 (DRB1*0401)) and promotes peptide binding to MHC II, which can be used in the study of immune regulation .
    J10-1
  • HY-N10899

    Parasite Infection
    Bruceine J, a quassinoid, is a nature product that could be isolated from fruits of Br. jaVanica. Bruceine J has anti-Babesial activity .
    Bruceine J
  • HY-116129

    FLT3 Apoptosis Cancer
    BPR1J-340 is a potent FLT3 inhibitor with an IC50 of ~25 nM. BPR1J-340 inhibits the phosphorylation of FLT3 and STAT5 and triggered apoptosis in FLT3-ITD + acute myeloid leukemia (AML) cells. BPR1J-340 exhibits significant anti-tumor activities .
    BPR1J-340
  • HY-N9312

    Others Inflammation/Immunology
    Ganoderic acid J is a natural terpenoid isolated from the Fungus Ganoderma lucidum. Ganoderic acid J possesses anti-inflammatory anti-inflammatory activity .
    Ganoderic acid J
  • HY-N12812

    Others Neurological Disease
    Tenuifoliose J is a neuroprotective oligosaccharide. Tenuifoliose J protects SY5Y cells induced by corticosterone (HY-B1618) .
    Tenuifoliose J
  • HY-112255

    Glucocorticoid Receptor Cancer
    J9 is a small molecule that reverses Dexamethasone (HY-14648) resistance in T-cell acute lymphoblastic leukemia. J9 is lethal to CUTLL1 cells only in the presence of Dexamethasone. J9 inhibits CUTLL1 cell growth with an EC50 of 28 μM in combination with Dexamethasone .
    J9
  • HY-N12720

    Others Cancer
    Cynanoside J is a C21 steroidal glycosides that can be obtained from Cynanchum taihangense. The IC50 values of Cynanoside J for HL-60, THP1, and Caco2 are 6.38, 5.82, and 6.76 μM, respectively. Cynanoside J can be used in cancer research .
    Cynanoside J
  • HY-149713

    ICMT Cancer
    J1-1 is an inhibitor of ICMT with an IC50 of 1.0 μM and has anticancer activity .
    J1-1
  • HY-163535

    HDAC DNA Methyltransferase Apoptosis Inflammation/Immunology Cancer
    J208 is a dual inhibitor for histone deacetylase (HDAC) and DNA methyltransferase (DNMT). J208 inhibits proliferation of cancer cells, as well as the migration/invasion of triple-negative breast cancer (TNBC) cells. J208 induces apoptosis, arrests the cell cycle at G0/G1 phase. J2008 activates the innate immune signalling pathway in TNBC, by inducing the expression of endogenous retroviruses (ERVs) .
    J208
  • HY-124653
    HSP27 inhibitor J2
    5+ Cited Publications

    J2

    HSP Cancer
    HSP27 inhibitor J2 (J2) is a HSP27 inhibitor, which significantly induces abnormal HSP27 dimer formation and inhibits a production of HSP27 giant polymers, thereby having an effect of inhibiting a chaperone function of the HSP27 and reducing a cell protection function thereof. HSP27 inhibitor J2 (J2) remarkably enhances the antiproliferative activity of 17-AAG and sensitizes cisplatin-induced lung cancer cell growth inhibition .
    HSP27 inhibitor J2
  • HY-N15387

    Drug Derivative Cancer
    Hericenone J (Compound 6) is an aromatic compound with anticancer activity, which is found in Hericium erinaceum. Hericenone J is cytotoxic and can significantly reduce the viability of HL-60 human acute promyelocytic leukemia cells with an IC50 value of 4.13 μM. Hericenone J is promising for research of leukemia .
    Hericenone J

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: